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Abstract  
Background and Aims: 
Primary biliary cirrhosis (PBC) patients experience significant impairment of quality of life (QOL). 
Studies to date examining relative contributions of different symptoms to QOL impairment in PBC, 
and biological associations have been limited by the unavailability of appropriate disease specific 
symptom quantification modalities.  
Methods: 
We applied the PBC-40, a recently developed, multi-domain disease specific QOL measure, to 54 
PBC patients to explore the inter-relationship of different symptoms, their biological associations, 
and correlation with physical functioning measured by accelerometry.  
Results: 
Two discrete and unrelated symptom complexes in PBC were identified focused on fatigue 
(together with cognitive and emotional dysfunction and other symptoms) and itch, with social 
dysfunction associating with both complexes. We confirmed no correlation between symptom 
severity and biological parameters of disease severity. There was a strong inverse correlation 
between physical activity (assessed over 6 days) and Fatigue (p<0.005), but not between physical 
activity and Itch.  Patients averaging <7500 steps per day had over 75% higher fatigue scores than 
patients averaging >7500 steps.  
Conclusions: 
We have demonstrated two independent symptom complexes in PBC centred around fatigue and 
itch, neither is associated with biological parameters of activity, and the fatigue-centred complex is 
associated with objective impairment of physical functioning.      
 
195 words 
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Introduction 
Primary biliary cirrhosis (PBC) is a chronic cholestatic liver disease with an autoimmune aetiology 
(1),(2). It is increasingly being appreciated that PBC patients frequently suffer from marked 
impairment of their quality of life (QOL) (3),(4),(5),(6). The major determinants of life quality 
impairment in PBC are fatigue (7),(8),(9),(10),(11) and pruritus (12),(13), with as yet poorly 
characterised effects resulting from, inter alia, cognitive impairment and issues relating to 
emotional and social function (5),(6). There is a broad consensus in the literature that the severity 
of at least one of the major symptoms of PBC (fatigue, the symptom with seemingly the greatest 
impact on QOL (6), shows no relationship to conventional parameters of liver disease severity 
(7),(8),(9). The implication of this observation is that the impact of symptoms on QOL is, to a 
significant degree, independent of disease stage and rate of progression, and should be viewed as 
an important clinical end-point in its own right (14),(15).  
 Study of the pathogenesis of the key symptoms of PBC, and evidence-based assessment 
of potential therapies, requires validated and reproducible symptom quantification methodologies 
to be available. Whilst relevant subjective (visual analogue scale and impact questionnaire) and 
objective (scratching activity modalities) measures are available for the study of pruritus (16), and 
are becoming available for fatigue (the fatigue impact score (FIS (9)), there remain limitations. The 
first limitation is that all the existing subjective measures used in PBC (including specific fatigue 
impact assessment tools such as the FIS and generic quality of life measures such as the SF-36) 
have either been largely or entirely derived in subject groups other than PBC patients, and have, in 
a number of cases, not been validated for use in PBC; factors which significantly limit their value in 
the study of PBC (4). The second limitation is that a number of the symptoms which appear to 
impact heavily on PBC patients are only poorly addressed by existing, non-PBC specific measures 
(4). The third limitation is that currently available symptom quantification modalities make it almost 
impossible to obtain an overview of the relative contributions of the different symptom types to 
overall quality of life impairment in PBC. Although generic measures, do allow an overview to be 
taken, they have limited appropriateness (in psychometric property terms) to PBC (4) and 
measuring of individual symptoms using such different modalities (electronic scratching activity 
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assessment for itch and fatigue impact scoring questionnaires for fatigue) precludes  “like with like” 
comparison.        
 In order to address these limitations we have devised and validated a psychometrically 
robust, multi-domain, disease-specific QOL measure for use in PBC (6). The six domains of the 
PBC-40 (Cognitive, Itch, Fatigue, Social, Emotional and (other) Symptoms) allow quantification of 
all the disease-related factors which impinge on the QOL of PBC patients using a common format. 
In the current study we have used the PBC-40 to address the inter-relationships of the individual 
symptoms of PBC, to study the relationship of all symptom groups to conventional parameters of 
disease severity (extending the previous work looking at such relationships to fatigue) and, for the 
first time in this disease, addressed the correlation between fatigue and other symptoms and a 
previously validated physical activity monitoring system to determine the links between perceived 
impairment of QOL and physical functioning.   
 
 
Newton: Quality of life in PBC  6 - 
Subjects & Methods 
Subjects  
All study subjects had definite or probable PBC (defined as the presence of all 3 of and 2 out of 3 
of AMA at titre of >1:80, cholestatic liver function tests and compatible or diagnostic liver histology 
respectively) and were recruited at random from a dedicated PBC clinic where all were receiving 
PBC–specialist follow-up. All subjects were women. Full clinical details of the study subjects are 
given in Table 1. All laboratory and clinical parameters were determined at the time of the study. 
None of the subjects participating in the study had advanced disease with complications of 
cirrhosis, were listed for liver transplantation or had undergone liver transplantation. Histological 
data refer to the most recent available liver biopsy for each patient performed for the clinical 
management of the patient. No biopsies were performed solely for the purposes of the study. No 
patients included in the study had treatment or co-morbidity that could have influenced the scores 
from the PBC-40. All subjects gave fully informed consent and this study was approved by the local 
research ethics committee. 
 
Health-Related Quality of Life Assessment  
All study subjects were asked to complete the PBC-40, a disease specific quality of life measure 
derived in, and validated for, self-completion use in PBC (6). All subjects completed the PBC-40 in 
the early afternoon (between 13:00 and 14:00). The PBC-40 has six domains; Cognitive, Itch, 
Fatigue, Social, Emotional and (other) Symptoms with individual questions scored in the range 1-5 
(with high scores denoting greater symptom impact and worse QOL).  
 
Physical Activity Monitoring 
Physical activity monitoring was performed by accelerometry over a constant 6 day period 
(Tuesday 14:00 to Monday 12:00) using the Actigraph system (Actigraph;MTI Health Services, 
USA). The monitors were belt-worn at the waist and initialised for total physical activity capture 
(measured as counts=16milliG per second with one minute cycles) with the additional secondary 
pedometer mode. Data were down-loaded after 6 days and analysed using the manufacturer’s 
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Windows-based software.  Normative values for activity levels (based on number of steps) have 
previously been established in the UK  
(http://www.nationalobesityforum.org.uk/APPG%201%20April%2004.pdf). Subjects taking under 
5000 steps per day are classified as “sedentary”, those taking between 5000-7499 steps/day as 
“low active”, between 7500-9999 steps/day as “somewhat active” and greater than 10000 
steps/day as “active”.   
  
Statistical Analysis 
Correlations between individual parameters were assessed by Spearmans test. Comparison of 
PBC-40 Fatigue domain scores in high and low activity patients was by one way ANOVA and by 
Student’s t-test. The p values denoting statistical significance for the correlations between 
individual PBC-40 domain scores, between individual PBC-40 domain scores and biological 
parameters of disease severity, and between individual domain scores and physical activity scores 
were adjusted for multiple testing using Bonferroni’s correction. Appropriate corrected thresholds 
for significance are given for each analysis.  
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Results 
Of the 60 patients enrolled in the study, 54 patients (90%) for whom full laboratory data were 
available successfully completed the PBC-40 in full and were included in the analysis. The mean 
item scores for the PBC-40 ranged from a high of 2.9 ± 1.1 (out of a maximum value of 5) for the 
Fatigue domain to a low of 1.4 ± 1.2 for the Itch domain (Table 2). The domain order (Fatigue and 
Emotional scoring highest and Itch lowest) closely matched that found in the original PBC-40 
validation study performed on a completely independent, nationally-recruited, patient cohort (6). 
This finding confirms the previous observations that fatigue is the symptom in PBC 40 with the 
highest relative impact on patient quality of life. All mean domain scores were marginally lower for 
the current study than in the validation study.  
 Initially we examined the inter-relationship of the symptoms of PBC quantified using the 
individual domains of the PBC-40. Individual Fatigue domain scores showed close correlations with 
Symptom, Cognitive, Social and Emotional domain scores (which, in turn all correlated with each 
other), but no correlation with Itch scores (Table 3, Figure 1). Itch scores, in contrast, showed  
only a single weak correlation (with Social domain scores) which was non-significant following 
correction for multiple testing (Table 3). Scores for the PBC-40 Fatigue domain showed a strong 
correlation with values for the FIS (Figure 2) previously validated for (9), and widely used in, the 
assessment of fatigue in PBC (8),(11),(17),(18). 
 Next we examined the inter-relationship of the individual PBC-40 domains with key 
biological parameters including bilirubin (an established marker of PBC disease severity) (Table 4), 
other parameters of disease severity and inflammatory activity including histological stage, age, 
duration of disease and other markers associated with fatigue inducing pathological processes 
(haemoglobin, blood glucose & thyroid stimulating hormone) (Table 4). No significant association 
patterns were seen.  
 Finally, given the prominence of fatigue as a factor in QOL impairment in PBC in this and 
other studies (5),(6), and previous evidence to suggest impairment in capacity for muscle function 
in fatigued patients (whether of central or peripheral origin) (19) we went on to assess the extent to 
which fatigue and the other domains of the PBC-40 correlated with objective measures of physical 
activity. Complete 6 day activity data were obtained from 45 of the 54 subjects (83%). Mean daily 
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pedometer mode values (expressed as number of steps) correlated strongly with fatigue as 
assessed by the PBC-40 Fatigue domain (Figure 3a, Table 5).  Only 11/45 subjects (24%) 
exceeded the UK recommended daily activity target of 10,000 steps per day (classified as “active”) 
(20).  No significant (following correction for multiple testing) correlations were seen between mean 
daily pedometer values and the other domains of the PBC-40.  In contrast to pedometer mode 
values the more sensitive total activity accelerometry mode mean daily values showed only a weak 
correlation with the Fatigue domain of the PBC-40 (which was not significant following correction 
for multiple testing (Figure 3)) and no correlation with any of the other domain scores (Table 5). 
The apparent discrepancy between physical activity data obtained using the two assessment 
modes is likely to reflect itch-related scratching activity being detected in the context of the more 
sensitive total activity mode, but not in the context of the pedometer mode, given that Itch domain 
scores show a negative correlation (albeit non-significant) with mean daily pedometer values, but a 
positive correlation with mean daily total activity.  
A mean of 7500 steps per day over the 6 day period appeared to be a key threshold for 
fatigue impact, with patients achieving an average of over 7500 steps per day (patients classified 
as “somewhat active” and “active”) having substantially lower PBC-40 Fatigue domain scores than 
patients not achieving an average of 7500 step per day (patients classified as “sedentary” and “low 
active” (Figure 4). The difference in the mean item point score between the groups (3.46 ± 0.8 
(<7500 steps) v 2.39 ± 0.9 (>7500 steps) was, given the minimum possible item score of 1, 77%. 
No correlation was seen between degree of physical activity and duration of disease which would 
be suggestive of deconditioning secondary to chronic disease (data not shown).  
Comparison of mean item score for each domain of the PBC-40, and the mean number of 
steps per day monitored over 6 days by Actigraphy, between PBC patients receiving UDCA 
therapy (n=34 (63%) and those not receiving UDCA therapy showed no significant difference for 
any parameter (Table 6)   
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Discussion 
In this study we set out to explore the inter-relationship of the characteristic symptoms of PBC 
through the use of a multi-domain disease specific QOL measure, the PBC-40, and to examine 
potentially key biological correlates. The relative scoring for the individual domains of the PBC-40 
(Fatigue and Emotional domain scoring the highest and Itch the lowest) mirrored closely that 
previously observed in a nationally recruited cohort who participated in the validation of the PBC-
40. This observation supports the PBC-40 as a reproducible and representative QOL measure in 
PBC. Interestingly, the individual mean domain scores observed in the current cohort were similar 
(but universally slightly lower) than the values seen in the validation study, suggesting that the 
current study cohort are reasonably representative of patients nationally in the UK and certainly do 
not represent a disproportionately high symptom impact patient group (we have previously 
highlighted the potential issues related to cohort selection in symptom impact studies in PBC) 
(9),(11). 
 Fatigue domain scores were found to correlate strongly with Symptom, Cognitive, 
Emotional and Social domain scores. Itch domain scores, in contrast, were only found to correlate 
with Social domain scores (and even this correlation was non-significant following correction for 
multiple testing). These relationship patterns suggest there are two independent symptom 
complexes in PBC, namely a fatigue complex (with overspill into, or association with, related 
cognitive and emotional features) and an itch complex (Figure 5). There appears to be, in the 
population studied at least, no link between these two complexes other than through a weak 
shared association with social dysfunction. We suspect that impaired social functioning associates 
with the fatigue complex as a result of impaired capacity to function in the social setting occurring 
as a consequence of energy-related problems, and, possibly, with the itch complex as a result of 
patients avoiding social contact because of embarrassment about scratching activity (a key theme 
identified in the qualitative phase of the PBC-40 derivation study (6). The strength of the apparent 
association between fatigue severity and cognitive impairment (as assessable by the PBC-40) 
would be strongly supportive of a significant CNS role for fatigue pathogenesis. The nature and 
degree of cognitive impairment seen in PBC has not been well studied to date and further work in 
this area is warranted.  
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PBC-40 Fatigue domain scores were also found to correlate strongly with FIS scores.  This 
suggests a commonality of fatigue-related themes quantified by the two measures. The strength of 
the PBC-40 lies in its disease specificity (with accordingly robust psychometric properties (4),(6) 
and its capacity to allow fatigue impact to be quantified in the full context of other important PBC 
symptoms rather than in isolation. This specificity precludes, however, its use in patients with other 
liver diseases and in control groups. The FIS retains, given its association with the PBC-40 Fatigue 
domain, and its applicability and validity in diverse disease settings, considerable value as a 
measure of fatigue severity in PBC patients when comparison with non-PBC controls is required.  
 In this study we have confirmed, using a more sensitive and disease specific measure of 
fatigue impact in a new patient cohort, the previously reported lack of association between any 
parameter of disease severity and fatigue impact (7),(8),(9),(5). This observation further supports 
the view that fatigue in PBC results from associated or secondary processes, rather than occurring 
as a direct consequence of liver damage. We have also extended this observation to the other 
domains of the PBC-40 suggesting that the lack of association between disease severity and QOL 
impact extends beyond fatigue to the other symptoms of PBC. This lends further weight to the view 
that the treatment of symptoms of PBC should be regarded as a therapeutic goal in its own right, 
rather than an outcome which will inevitably be achieved by modifying the natural history of the 
underlying liver disease (14),(15). In contrast to a recent report (5) we found that fatigue severity 
was as great in PBC patients taking UDCA as in those not taking UDCA. Moreover, there was no 
difference in physical activity between the two groups. We could find no evidence, therefore, to 
support the view that UDCA is beneficial for fatigue in PBC. This conclusion is supported by our 
recent demonstration of no effect of UDCA therapy on fatigue in a cohort of PBC patients followed 
up for 4 years (21). 
 In contrast to the lack of association between parameters of disease severity and fatigue 
and the other domains of the PBC-40, a significant inverse correlation was seen between the mean 
numbers of steps taken per day assessed using the Actigraph system programmed in the 
pedometer mode, and fatigue severity as assessed using both the PBC-40 Fatigue domain and the 
FIS (data not shown). No association was seen, in contrast, with the itch symptom complex. These 
observations suggest that, whatever the responsible mechanisms, the perception of impairment of 
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physical capacity in PBC patients is matched by actual reduction in that capacity. Although able to 
quantify the decreased physical activity associated with fatigue perception in our population the 
experimental approach adopted is not able to determine the nature of the link between the two 
phenomena. It is, therefore, not clear whether lowered physical activity results in patients feeling 
fatigued, whether patients are unable or unwilling to exercise to the same degree as a 
consequence of their sensation of fatigue, or whether perception of fatigue and activity impairment 
are unrelated sequelae of a shared underlying process. This issue is of potential importance as 
were the sensation of fatigue to be a consequence of reduced physical activity then approaches 
aimed at improving exercise capacity (such as staged exercise programmes) may be of 
therapeutic benefit. 
 Finally, our demonstration of an association between physical activity and severity of 
perceived fatigue suggests that the approach used, Actigraph assessment in pedometer mode, 
may have applications as an objective measure of symptom impact for the use in the study of 
fatigue pathogenesis and treatment in PBC. The value of objective measures as an adjunct to 
subjective approaches to symptom assessment has been clearly demonstrated in the study of 
pruritus pathogenesis and management, where scratching activity quantification has become the 
gold standard assessment technique (22). Activity monitoring may, in particular, allow the rapid 
assessment of interventions, as “fatigue” is assessed over a 6 day period which contrasts with the 
4 weeks over which patients are asked to consider symptom severity when completing the PBC-
40. Our experience of activity monitoring in this study does, however, give some key pointers to the 
potential pitfalls which could be encountered in the application of this technique in the clinical 
setting. The first is that use of the more sensitive total activity derived by accelerometry appeared 
to detect minor physical activity such as scratching activity related to itch. The use of such 
sensitive modes therefore may detect “non-productive” activity giving a falsely high picture of total 
activity. The use of less sensitive modes which build in a threshold for meaningful activity appears 
more productive and, potentially, opens the way for the use of simpler (and cheaper) systems than 
that used in this study. The second potential pitfall is the quite marked intra-individual day to day 
variation in detected physical activity (mean 36% ± 25% [range 8-151%]). This observation, which 
raises an interesting parallel with the recurring theme of marked day to day variation in fatigue 
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severity identified in the qualitative phase of the PBC-40 derivation study (6), does mean that multi-
day testing is essential. Although patient satisfaction with this was high in our study, and 
compliance accordingly good, failure of data capture was not, in our experience, uncommon over 
six days of assessment.       
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Tables 
Table 1: Clinical characteristics of study participants 
 
Parameter Mean Value (SD) 
Age 63.0 (9.4) 
Bilirubin (µmol/l) 10.4 (9.1) 
Albumin (g/l) 40.8 (3.9) 
Prothrombin Time (secs) 12.2 (1.0) 
ALT U/l 42.0 (38.7) 
Alkaline Phosphatase U/l 166 (101) 
IgG g/l 12.3 (3.1) 
IgM g/l 3.0 (2.1) 
AMA (titre) 321 (260) 
Biopsy (%) 85% 
Advanced Disease 
(Scheuer Stage III/IV)  
(% of Those Biopsied)  
50% 
Disease Duration 
(years) 
7 (4) 
UDCA Therapy (%) 63% 
UDCA Dose (mg/day) 760 (223) 
TSH mu/l 2.4 (2.3) 
Haemoglobin g/dl 13.5 (1.3) 
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Table 2: Mean item scores for the individual domains of the PBC-40. Maximum possible score per 
item is 5 and minimum per item 1.  
 
Item Fatigue Emotional Social Cognitive Symptoms Itch 
Mean 
Score (SD) 
2.9 (1.1) 2.8 (1.1) 2.6 (1.0) 2.5 (1.2) 2.3 (0.7) 1.4 (1.2) 
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Table 3: Inter-domain correlations (r2 values) for the PBC-40. Significant correlations (threshold for 
significance p<0.003 following correction for multiple testing) are denoted in bold. ** denotes 
p<0.0001. 
 
 Symptoms Itch Fatigue Cognitive Social Emotional 
Symptoms x 0.06 0.39**** 0.33**** 0.26**** 0.28**** 
Itch  x 0.07 0.04 0.10 0.06 
Fatigue   x 0.50**** 0.64**** 0.54**** 
Cognitive    x 0.52**** 0.37**** 
Social     x 0.63**** 
Emotional      X 
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Table 4: Correlations (r2 values) between PBC-40 domains and biological disease parameters. No 
correlations were significant (all p<0.01 with threshold for significance of p<0.0008 following 
correction for multiple testing).  
 
 Symptoms Itch Fatigue Cognitive Social Emotional 
Bilirubin 0.02 0.02 0.00 0.00 0.02 0.00 
Albumin 0.01 0.10 0.01 0.00 0.04 0.04 
PT 0.08 0.02 0.05 0.01 0.01 0.04 
Alk Phos 0.00 0.04 0.00 0.01 0.00 0.00 
ALT 0.00 0.05 0.00 0.02 0.00 0.00 
IgM 0.13 0.01 0.07 0.05 0.03 0.00 
IgG 0.02 0.01 0.08 0.03 0.04 0.09 
AMA Titre 0.03 0.05 0.01 0.00 0.01 0.02 
Stage 0.00 0.00 0.00 0.01 0.00 0.00 
Disease 
Duration 
0.00 0.02 0.07 0.02 0.07 0.04 
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Table 5: Correlations (r2 values) between the PBC-40 domains and 6 day physical activity 
measured by Actigraph in pedometer (total steps) and all activity (total activity) modes. Significant 
correlations (threshold for significance p<0.004 following correction for multiple testing) are 
denoted in bold. ** denotes p<0.0001. 
 
 Symptoms Itch Fatigue Cognitive Social Emotional 
Total 
Steps 
0.11 0.00 0.21**** 0.10 0.10 0.11 
Total 
Activity 
0.00 0.02 0.08 0.04 0.08 0.07 
 
 
Newton: Quality of life in PBC  22 - 
Table 6: PBC-40 mean domain item scores and 6 day physical activity measured by Actigraph in 
pedometer (total steps) mode in PBC patients receiving and not receiving UDCA therapy. Values 
given are mean (SD). No significant differences were seen between the two groups for any 
parameter. 
 
 Symptoms 
Domain 
Itch 
Domain 
Fatigue 
Domain 
Cognitive 
Domain 
Social 
Domain 
Emotional 
Domain 
Total Steps 
UDCA 
 
2.2 (0.5) 1.5 (1.3) 2.8 (1.2) 2.5 (1.3) 2.6 (1.1) 2.8 (1.1) 7281 (2454) 
No UDCA 
 
2.5 (0.9) 1.2 (1.3) 3.0 (1.1) 2.5 (1.3) 2.6 (1.1) 2.8 (1.1) 8264 (2899) 
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Figure 1: Correlation between individual patient PBC-40 fatigue domain scores and a) Symptoms 
domain scores, b) Itch domain scores, c) Cognitive domain scores, d) Social domain scores & e) 
Emotional domain scores. 
a) b)                                                c)
d) e)         
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Figure 2: Correlation between individual patient PBC-40 fatigue domain scores and FIS scores. 
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Figure 3: Correlations between 6 day mean physical activity detected using the Actigraph 
pedometer (a & c) or total activity mode (b & d) and individual PBC-40 Fatigue domain (a & b) and 
Itch domain scores (c & d). 
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Figure 4: PBC-40 Fatigue domain scores in patients with mean daily activity of greater than and 
less than 7500 steps per day (75% of the UK recommended “healthy living” target of 10,000 steps 
per day.  
<7500 >750011
22
33
44
55
p=0.0001
Mean Steps Per Day (6 Days)
PB
C-
40
 
Fa
tig
u
e
Do
m
ai
n
 
(11
-
55
)
 
Newton: Quality of life in PBC  27 - 
 
Figure 5: A model for the inter-relationship of the domains of the PBC-40. 
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